drugset / Trial / NCT00934362
Effect of Lucinactant on Mucus Clearance in Cystic Fibrosis Lung Disease
Phase 2
Completed
16 enrolled
University of North Carolina, Chapel Hill
Cystic Fibrosis Foundation · collabWindtree Therapeutics · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
Mucus clearance is impaired in cystic fibrosis. Inhaled surfactants may reduce adhesive forces between mucus and airway surfaces and improve mucus clearance. This in turn my improve lung health. The investigators propose to measure mucus clearance before and after lucinactant or vehicle administration in patients with cystic fibrosis.
Timeline
- Start
- 2008-10
- Primary completion
- 2010-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lucinactant | Peptide | 120 mg | Inhaled |